Inactive Instrument

Analyst Reco. OHR Pharmaceutical Inc Nasdaq

Equities

North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
Oppenheimer Downgrades NeuBase Therapeutics to Perform From Outperform, Removes $15 Price Target	22-10-21	MT
NeuBase Therapeutics Downgraded by RBC to Sector From Outperform, Price Target Slashed to $1 From $12 Amid Restructuring; Speculative Risk Kept	22-10-18	MT
Chardan Capital Downgrades NeuBase Therapeutics to Neutral from Buy	22-10-17	MT
Oppenheimer Adjusts NeuBase Therapeutics Price Target to $15 From $17, Maintains Outperform Rating	22-08-23	MT
Chardan Research Cuts Price Target on NeuBase Therapeutics to $7 From $9, Reiterates Buy Rating	22-08-12	MT
HC Wainwright Adjusts NeuBase Therapeutics' Price Target to $10 From $15, Keeps Buy Rating	22-05-31	MT
Chardan Capital Adjusts NeuBase Therapeutics' Price Target to $9 from $18, Keeps Buy Rating	22-05-13	MT
NEUBASE THERAPEUTICS : RBC Trims Price Target on NeuBase Therapeutics to $15 From $16 to Reflect Operating Expenses; Outperform, Speculative Risk Kept	21-08-16	MT
NEUBASE THERAPEUTICS : HC Wainwright Adjusts Price Target on NeuBase Therapeutics to $15 From $18, Maintains Buy Rating	21-06-01	MT

No results for this search